Your browser doesn't support javascript.
loading
Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.
Ueda, Munetaka; Tanimoto, Tetsuya; Murayama, Anju; Ozaki, Akihiko; Kami, Masahiro.
Affiliation
  • Ueda M; Japanese Red Cross Medical Center, Tokyo, Japan.
  • Tanimoto T; Navitas Clinic Kawasaki, Kawasaki, Japan.
  • Murayama A; Medical Governance Research Institute, Tokyo, Japan.
  • Ozaki A; Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan.
  • Kami M; Medical Governance Research Institute, Tokyo, Japan.
Clin Pharmacol Ther ; 111(3): 545-547, 2022 03.
Article in En | MEDLINE | ID: mdl-33882157
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Drug Approval / Amides Type of study: Clinical_trials / Prognostic_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Clin Pharmacol Ther Year: 2022 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Drug Approval / Amides Type of study: Clinical_trials / Prognostic_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Clin Pharmacol Ther Year: 2022 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos